We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02378207
Recruitment Status : Completed
First Posted : March 4, 2015
Results First Posted : November 18, 2019
Last Update Posted : November 18, 2019
HIV Vaccine Trials Network
Sanofi Pasteur, a Sanofi Company
Statens Serum Institut
Information provided by (Responsible Party):

Brief Summary:
The aims of the phase 1b trial described here are to facilitate identification of assays and immune responses that could then be evaluated as correlates of risk and correlates of protection in efficacy studies and ultimately to provide leads for biomarkers of protection against tuberculosis. This study will complement one ongoing study (NCT02075203) evaluating the prevention of M. Tuberculosis infection using H4:IC31 (also known as AERAS-404).

Condition or disease Intervention/treatment Phase
Tuberculosis Biological: H4:IC31 Biological: H56:IC31 Biological: BCG Biological: Control Sodium Chloride 0.9% Phase 1

Detailed Description:

This study proposes to further evaluate the safety and immunogenicity of H4:IC31, H56:IC31, and BCG revaccination. The study will be conducted in previously BCG vaccinated healthy adolescents, and will entail a thorough immunogenicity evaluation of these regimens incorporating unbiased systems vaccinology approaches and novel assessments of baseline and elicited responses that may impact vaccine responses. A major goal for this study is to generate immunological data on a wide range of immune responses using a variety of approaches including validated assessments, unbiased strategies, and novel exploratory assays to increase the likelihood of detecting responses correlating with risk or protection in the prevention of infection study. Investigators contributing to the proposed study have participated in a correlates analysis for an HIV vaccine exhibiting modest efficacy in which 2 correlates of risk were identified.

An additional aim of this study is to explore factors affecting vaccine induced responses that may also impact efficacy. For example, it is hypothesized that exposure to environmental mycobacteria may alter protection provided by BCG vaccination. Reagents for evaluating levels of exposure to environmental mycobacteria are in development as part of a concurrent collaborative study. An exploratory objective for this trial is to apply these reagents to examine whether such exposures influence immune responses elicited by the study vaccine and regimens.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 84 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Placebo-controlled, Partially Blinded Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of BCG Revaccination, H4:IC31, and H56:IC31 in Healthy, HIV-1-Uninfected Adolescent Participants
Study Start Date : May 2015
Actual Primary Completion Date : October 31, 2016
Actual Study Completion Date : December 9, 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Group 1 H4:IC31
15 mcg H4/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
Biological: H4:IC31
H4 contains Mtb antigens Ag85B and TB10.4

Experimental: Group 2 H56:IC31
5 mcg H56/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
Biological: H56:IC31
H56 contains Mtb antigens ESAT-6, and Rv2660c

Active Comparator: Group 3 BCG (2-8 x 105 CFU)
Administered IM as 0.1 mL in either deltoid muscle at Day 0.
Biological: BCG
Placebo Comparator: Group 4 Control Sodium Chloride 0.9%
Administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
Biological: Control Sodium Chloride 0.9%

Primary Outcome Measures :
  1. Number of Participants With Adverse Events [ Time Frame: Up to 8 months ]
    The number of solicited and unsolicited adverse events (AEs), including serious adverse events (SAEs), recorded post-vaccination for all participants.

  2. Percentage of Participants With Response Rates to TB Antigens as Compared to Baseline [ Time Frame: Days 70 and 168 ]
    Flow cytometry was used to examine TB Mb-specific CD4+ and CD8+ T-cell responses using the ICS assay. The antigens used to stimulate cells in this assay included peptide pools for the vaccine-matched proteins (Ag85B, ESAT-6, Rv2660c, and TB 10.4) as well as complex TB antigens (TB whole cell lysate [TB WCL], and BCG Pasteur strain.

Secondary Outcome Measures :
  1. Evaluate Humoral Responses Elicited by the Different Vaccine Regimens. [ Time Frame: Up to day 168. ]
    Vaccine-specific binding antibodies elicited by the vaccine regimens as determined by multiplex antibody assay and/or enzyme-linked immunosorbent assay (ELISA).

  2. * Evaluate Immune Response From Vaccine Regimens by Measuring Early (Innate) Vaccine-induced Peripheral Blood Transcription Profiles; Determine Which Responses Are Associated With Antigen-specific Adaptive Responses * Evaluate Adaptive Immune Response. [ Time Frame: Up to day 168 ]
    • Changes in gene expression measured in longitudinally-collected blood samples relative to samples collected at baseline. The transcriptional profiles will be correlated with antigen-specific adaptive responses measured in Primary objective 2.
    • Transcriptional analysis of antigen-stimulated peripheral blood mononuclear cells (PBMC) at 2 weeks post vaccination will be performed..

  3. Evaluate Changes in Innate Cells in Response to the Vaccine Regimens [ Time Frame: Up to day 168 ]
    Blood concentrations of innate immune cell populations including lymphocyte populations, dendritic cells, monocytes, and granulocytes before and after vaccination

  4. Measure Non-classical Major Histocompatibility Complex (MHC)-Restricted T-cell Vaccine-induced Responses, Such as to Mycobacterial Lipids (CD1-restricted) and Metabolites (MR1-restricted). [ Time Frame: Up to day 168 ]
    • Frequency of CD4+, CD8+, and CD4/CD8 double-negative T-cell responses restricted by CD1 (recognizing specific Mtb lipids) before and after BCG revaccination in Group 3 participants.
    • Frequency of mucosal-associated invariant T-cells (MAIT) restricted by MR1 (recognizing vitamin B metabolites) before and after BCG revaccination in Group 3 participants

  5. Evaluate QFT-GIT and ESAT-6 Free IGRA Discordance and Conversion/Reversion Rate During the Course of the Trial. [ Time Frame: Up to day 168 ]
    • Magnitude and positivity of interferon (IFN)-γ release using QFT-GIT ELISA in QFT-GIT tests.
    • Magnitude and positivity of IFN-γ release using QFT-GIT ELISA in ESAT-6 free IGRAs.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   12 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Age of 12 to ≤ 17 years at enrollment
  2. Minimum weight ≥ 40 kg
  3. Previous BCG vaccination at least 5 years ago documented by scarification or medical card
  4. No evidence of active TB disease, as determined by history, physical examination and, if deemed appropriate, sputum investigation and / or chest x-ray.
  5. Negative QFT-GIT test at screening, using the manufacturer's recommended threshold of 0.35 IU/mL
  6. Assessed by the clinic staff as being at low risk for HIV infection
  7. Hemoglobin ≥ 11.7 g/dL for females, ≥ 12.5 g/dL for males
  8. Negative HIV-1 and -2 blood test
  9. Agree to consistently use effective contraception for sexual activity that could lead to pregnancy from at least 20 days prior to enrollment through the last required protocol clinic visit.

(additional minor criteria not added due to space constraints)

Exclusion Criteria:

  1. Blood products received within 120 days before first vaccination
  2. Investigational research agents received within 182 days before first vaccination
  3. Intent to participate in another study of an investigational research agent during the planned duration of the HVTN 602 / AERAS A-042 study
  4. Pregnant or breastfeeding
  5. History of alcohol or drug abuse
  6. A significant contact with active TB disease: for example, shared residency with an individual receiving anti-TB treatment, or with an individual known to have incompletely treated culture or smear positive TB
  7. TB prophylaxis within 90 days prior to enrollment
  8. History of treatment for active TB disease or latent Mtb infection
  9. Positive and indeterminate QFT-GIT result
  10. Received a tuberculin skin test (TST) within 90 days prior to enrollment
  11. Vaccines and other Injections
  12. Immunosuppressive medications received within 168 days before first vaccination.
  13. Serious adverse reactions to vaccines including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain.
  14. Immunoglobulin received within 60 days before first vaccination
  15. Autoimmune disease Not excluded: mild, well-controlled psoriasis
  16. Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. Including but not limited to: Diabetes mellitus type 1 or type 2, Thyroidectomy, or Thyroid disease, Asthma, Asplenia, Bleeding disorders, malignancy, Seizure disorder, and Angioedema

(additional minor criteria not added due to space constraints)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02378207

Layout table for location information
South Africa
Desmond Tutu HIV Foundation
Cape Town, South Africa
Sponsors and Collaborators
HIV Vaccine Trials Network
Sanofi Pasteur, a Sanofi Company
Statens Serum Institut
Layout table for investigator information
Study Chair: Linda-Gail Bekker, MD Desmond Tutu HIV Centre
Study Chair: Jim Kublin, MD HVTN Core, FHCRC
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Aeras
ClinicalTrials.gov Identifier: NCT02378207    
Other Study ID Numbers: HVTN 602 / AERAS A-042
First Posted: March 4, 2015    Key Record Dates
Results First Posted: November 18, 2019
Last Update Posted: November 18, 2019
Last Verified: January 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Mycobacterium Infections
Actinomycetales Infections
Gram-Positive Bacterial Infections
Bacterial Infections
Bacterial Infections and Mycoses